francesca romano

Dr. francesca romano


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
EREdda Russo
Edda Russo
LGLeandro Di Gloria
Leandro Di Gloria
MCMatteo Cerboneschi
Matteo Cerboneschi
SSSerena Smeazzetto
Serena Smeazzetto
GBGian Paolo Baruzzi
Gian Paolo Baruzzi
Amedeo AmedeiAmedeo Amedei
Amedeo Amedei
In this exploratory study, we investigate the variation in the facial skin microbiome architecture through aging and their functional association with host genetic factors in a cohort of healthy women, living in the same area and without cutaneous diseases. Notably, facial skin microbiota (SM) samples were collected from a cohort of 15 healthy Caucasian females, firstly divided into three age groups (younger women aged 20–35 years old; middle aged women of 36–52 years old; and older women aged 53–68 years old). Then, the recruited cohort was divided into two groups based on their facial hydration level (dry and normal skin). The facial SM revealed a different composition in the three analyzed aging groups and between normal and dry skins. The middle-aged women also revealed functional variations associated with collagen biosynthesis and oxidative stress damage repair. Otherwise, the association between selected host SNPs (single nucleotide polymorphisms) and the facial SM profile showed significant associations, suggesting a negative correlation with collagen metabolism and ROS damage protection. Finally, the composition and functionality of the facial SM seemed to affect the aging process through the two aging-correlated pathways of host ROS damage repair and collagen metabolism. Our exploratory data could be useful for future studies characterizing the structure, function, and dynamics of the SM in the aging process to design personalized therapeutic agents focusing on potential genomic targets, microbes, and their metabolites.

27 June 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AMAlessandra Mongia
Alessandra Mongia
FRfrancesca romano
francesca romano
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
BPBenedetta Peruzzi
Benedetta Peruzzi
SBSara Bencini
Sara Bencini
AFAlessandra Fanelli
Alessandra Fanelli
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by bone marrow expansion and the proliferation of one or more myeloid cell lineages, predominantly driven by the expression of the constitutively active fusion product tyrosine kinase BCR:ABL1. Rarely, CML patients directly develop a blast crisis (BC), mostly of myeloid origin. CML at blast crisis with a T-cell phenotype at diagnosis, without any prior history of CML, is extremely rare. Herein, we describe one rare CML case, in a young man showing an unusual and early T-lymphoid blastic crisis at diagnosis, as the first onset of a previously unknown CML. The multidisciplinary collaboration between laboratorians and clinicians for the diagnosis and management of this atypical case was crucial in outlining both a targeted pharmacological treatment and a successful hematopoietic stem cell transplantation.

6 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
VBValentina Becherucci
Valentina Becherucci
FRfrancesca romano
francesca romano
EREdda Russo
Edda Russo
The analysis of non-blood biological fluids, including cerebrospinal fluid (CSF), serous effusions, and synovial fluid, plays a central role in laboratory medicine by providing essential diagnostic and prognostic information for neurological, infectious, inflammatory, and neoplastic diseases. However, the interpretation of these specimens remains challenging because it requires the integration of heterogeneous biochemical, cytological, microbiological, molecular, and clinical data, often in the absence of standardized analytical workflows. Artificial intelligence (AI), particularly Machine Learning (ML) and Deep Learning (DL), is emerging as a powerful approach for extracting clinically relevant information from complex multidimensional datasets beyond the capabilities of conventional analytical methods. AI-driven Clinical Decision-Support Systems (CDSSs) can integrate laboratory findings with clinical, demographic, imaging, and multi-omics data, supporting diagnostic interpretation, patient stratification, and personalized clinical decision-making. At the same time, the convergence of AI with proteomics, metabolomics, metagenomics, and other omics technologies is accelerating biomarker discovery and advancing precision laboratory medicine. Current evidence indicates different levels of maturity across biological fluids. AI-assisted interpretation of CSF biomarkers and digital cytology of serous effusions currently show the strongest clinical evidence, whereas applications involving synovial fluid and integrated multi-omics remain largely exploratory. Although important technical, methodological, and regulatory challenges still limit widespread clinical implementation, AI has the potential to improve diagnostic accuracy, reduce interpretative variability, and support more integrated diagnostic workflows. This mini-review summarizes current and emerging AI applications in non-blood biological fluid analysis, with particular emphasis on biomarker discovery, CDSS, multi-omics integration, current evidence, existing limitations, and future perspectives for precision laboratory medicine.

30 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VBValentina Becherucci
Valentina Becherucci
FRfrancesca romano
francesca romano
EREdda Russo
Edda Russo
The analysis of non-blood biological fluids, including cerebrospinal fluid (CSF), serous effusions, and synovial fluid, plays a central role in laboratory medicine by providing essential diagnostic and prognostic information for neurological, infectious, inflammatory, and neoplastic diseases. However, the interpretation of these specimens remains challenging because it requires the integration of heterogeneous biochemical, cytological, microbiological, molecular, and clinical data, often in the absence of standardized analytical workflows. Artificial intelligence (AI), particularly Machine Learning (ML) and Deep Learning (DL), is emerging as a powerful approach for extracting clinically relevant information from complex multidimensional datasets beyond the capabilities of conventional analytical methods. AI-driven Clinical Decision Support Systems (CDSS) can integrate laboratory findings with clinical, demographic, imaging, and multi-omics data, supporting diagnostic interpretation, patient stratification, and personalized clinical decision-making. At the same time, the convergence of AI with proteomics, metabolomics, metagenomics, and other omics technologies is accelerating biomarker discovery and advancing precision laboratory medicine. Current evidence indicates different levels of maturity across biological fluids. AI-assisted interpretation of CSF biomarkers and digital cytology of serous effusions currently show the strongest clinical evidence, whereas applications involving synovial fluid and integrated multi-omics remain largely exploratory. Although important technical, methodological, and regulatory challenges still limit widespread clinical implementation, AI has the potential to improve diagnostic accuracy, reduce interpretative variability, and support more integrated diagnostic workflows. This mini-review summarizes current and emerging AI applications in non-blood biological fluid analysis, with particular emphasis on biomarker discovery, CDSS, multi-omics integration, current evidence, existing limitations, and future perspectives for precision laboratory medicine.

25 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FRfrancesca romano
francesca romano
VBValentina Becherucci
Valentina Becherucci
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
EREdda Russo
Edda Russo
AMAlessandra Mongia
Alessandra Mongia
FBFRANCESCA BRUGNOLO
FRANCESCA BRUGNOLO
Background: The Sysmex XN series (XN-1000 and XN-9100, Sysmex Corporation, Kobe, Japan) represents a latest-generation automated hematology platform integrating fluorescence-based technologies and multi-channel analysis (WDF and WPC) to improve leukocyte characterization. This study aimed to evaluate the performance of the Sysmex XN series in detecting leukocyte abnormalities flagged during routine complete blood count analysis in a large cohort of healthy donors, using morphological assessment and flow cytometry as confirmatory methods. Methods: Approximately 8000 healthy blood donors from the AOU Meyer Transfusion Centre were evaluated between 2021 and 2024. All samples underwent CBC analysis using the XN-1000 and XN-9100 analyzers with the WDF channel. Samples showing WBC-related flags were subjected to reflex testing with the WPC channel, followed by digital blood smear review using the DI-60 system (CellaVision, Lund, Sweden) and flow cytometric immunophenotyping. Results: WDF flags for “blasts/abnormal lymphocytes” were identified in 23 samples. Two samples were negative on WPC analysis as well as on morphological and flow cytometric evaluation. Among the remaining cases, WPC analysis identified flags for abnormal lymphocytes, atypical lymphocytes, or blasts, which were variably associated with reactive changes, transient immune activation, or clonal lymphoproliferative conditions. In one donor, monoclonal B-cell lymphocytosis was diagnosed by flow cytometry. Overall, reactive morphological features confirmed by flow cytometry were observed in approximately 50% of flagged cases. Conclusions: WPC analysis provides relevant additional diagnostic information and demonstrates higher specificity compared with the WDF channel alone; however, it does not fully resolve all instrument-generated flags, confirming the essential role of morphological assessment. Interestingly, the frequent occurrence of inflammatory profiles in recently vaccinated donors suggests that transient immune activation may influence leukocyte flagging. Larger studies are warranted to further investigate this association and to optimize the diagnostic performance of the WPC channel in donor screening.

19 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
DRDomenico Romeo
Domenico Romeo
ABAlessandro Bonari
Alessandro Bonari
EREdda Russo
Edda Russo
PNPamela Nardiello
Pamela Nardiello
FRfrancesca romano
francesca romano
Background/Objectives: Modern automated hematology analyzers combine quantitative cell counting with proprietary algorithms for automated morphological interpretation. While analytical validation traditionally focuses on measurement agreement, less attention has been paid to the evaluation of algorithm-assisted morphological interpretation. This study compared the analytical performance and automated morphological flagging of the Sysmex XN-9100 and Mindray BC-7800/BC-7900 platforms under routine laboratory conditions. Methods: A total of 183 peripheral blood samples collected between October 2025 and February 2026 were analyzed in parallel using both platforms. The study population included healthy individuals and patients with hematological and non-hematological disorders. Analytical agreement for complete blood count (CBC) and leukocyte differential parameters was assessed using Passing–Bablok regression and Bland–Altman analyses. Automated morphological flagging was evaluated in 157 samples using expert optical microscopy as the reference standard. McNemar’s test, Cohen’s kappa coefficient, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Results: Excellent agreement was observed for the principal CBC parameters, including white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, and platelet count (correlation coefficients: 0.981–1.000), with minimal proportional bias. Greater variability was found for monocytes, eosinophils, and basophils, particularly at low cell concentrations. Although analytical performance was highly comparable, the two platforms showed different morphological flagging profiles. Both analyzers achieved high negative predictive values (>90%), while differences in sensitivity and specificity across individual flag categories reflected distinct algorithm-assisted classification strategies. Agreement with expert microscopy ranged from fair to moderate for most pathological flags. Conclusions: The Mindray BC-7800/BC-7900 and Sysmex XN-9100 demonstrated excellent analytical agreement for routine CBC testing. However, comparable analytical performance did not necessarily correspond to identical automated morphological interpretation. These results indicate that evaluation of modern hematology analyzers should include both analytical performance and agreement between automated flags and expert microscopy.